Efforts to rein in the cost of prescription drugs took a new direction when President Biden called on the US Food and Drug Administration to communicate with the US Patent and Trademark Office about misuse of the patent system to delay generic drug and biosimilar competition.
The mandate, included in Biden’s June 2021 executive order on “Promoting Competition in the American Economy,” led the two agencies...